IL‐1β agents have demonstrated significant efficacy in the clinical treatment of cryopyrin‐related auto‐inflammatory syndrome, and subsequent clinical trials of other NLRP3‐associated diseases have also been carried out.14, 15. The gene discussed is NLRP3; the disease is autoinflammatory syndrome.